manner with a maximal effect at a concentration of 50 nM (161%) or 50 M (205%), respectively. When added together, low concentrations of U-II (50 nM) and 5-HT (1 M) interacted synergistically in inducing [ 3 H]thymidine incorporation (382%). These effects on [ 3 H]thymidine incorporation were paralleled by an increase in cell number. The Gprotein inactivator GDP-␤-S (100 M), protein kinase C (PKC) inhibitor Ro31-8220 (0.1 M), c-Src tyrosine kinase inhibitor PP2 (1 M), and mitogen-activated protein kinase (MAPK) kinase inhibitor PD098059 (10 M) inhibited the mitogenic effects of U-II and 5-HT and also their interaction in inducing [
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Vascular smooth muscle cell (VSMC) proliferation induced by various growth factors has been implicated in a wide variety of pathological processes including hypertension, atherosclerosis and restenosis after angioplasty. We investigated the interactions among well-known potent vasoconstrictor substances, endothelin-1 (ET-1), angiotensin II (Ang II), and serotonin (5-HT) on VSMC proliferation. Growth-arrested rabbit VSMCs were incubated with different concentrations of ET-1 in the absence or presence of Ang II, 5-HT, or both. VSMC proliferation was examined by increases in [ 3 H]thymidine incorporation into DNA and cell number. ET-1, Ang II and 5-HT stimulated DNA synthesis in a dosedependent manner. ET-1 had a maximal effect at a concentration of 0.5 M (259% of control), Ang II at 1 M (173%), and 5-HT at 50 M (205%). When added together, ET-1 (0.1 M) and Ang II (1 M) synergistically induced DNA synthesis (341%). When the vasoconstrictors were tested in combination, even non-mitogenic concentrations of ET-1 (0.01 nM) potentiated 5-HT (5 M)-induced DNA synthesis (404%). Coincubation of ET-1 (0.01 M) with Ang II (1 M) and 5-HT (5 M) synergistically induced DNA synthesis (566%). These effects on DNA synthesis were paralleled by an increase in cell number. The ET A/B non-selective receptor antagonist, TAK044 (1 M) and the ET A receptor antagonist, BQ123 (1 M), but not the ET B receptor antagonist, BQ788
(1 M), inhibited the mitogenic effect of ET-1 and its interaction with Ang II or 5-HT. In addition, TAK044 (1 M) or BQ123 (1 M) along with the AT 1 receptor antagonist, candesartan (1 M), the 5-HT 2A receptor antagonist, sarpogrelate (10 M), or both, inhibited the interactions of ET-1 with Ang II or 5-HT. Our results suggest that Ang II and 5-HT could potentiate ET-1-induced VSMC proliferation. Inhibition of ET A , AT 1 , and 5-HT 2A may be effective in the treatment of VSMC proliferative disorders associated with hypertension, atherosclerosis and restenosis after angioplasty.
Key Words: Angiotensin II, Serotonin, Endothelin-1 We examined the mechanism of action of lysophosphatidylcholine (lyso-PC), which is suggested to be involved in the pathogenesis of atherosclerosis and inflamatory disorders, and its interaction with well-known vasoactive agents such as hydrogen peroxide (H 2 O 2 ), thromboxane A 2 (TX-A 2 ), serotonin (5-HT), angiotensin II (Ang-II), endothelin-1 (ET-1), or urotensin II (U-II) on vascular smooth muscle cell (VSMC) proliferation. Growth-arrested rabbit VSMCs were incubated with given concentrations of lyso-PC with H 2 O 2 , TX-A 2 , 5-HT, Ang-II, ET-1, or U-II. 
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